Dr. Stephanie Lheureux study chair discusses the OV.25 study Wednesday, October 24, 2018 Dr. Stephanie Lheureux discusses the CCTG OV.25 Ovarian Cancer Trial that explores the possibility of a prevention strategy for ovarian cancer. The OV.25 study targets woman who have the confirmed genetic mutation BRCA1 or BRCA2. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer and researchers want to understand if an anti-inflammatory intervention can help reduce the risk.
